OUR TEAM

Our leadership team possesses rich and diverse industry knowledge, a passion for science and a shared commitment to help transform lives.

Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.

  • Leonard S. Schleifer

    Leonard S. Schleifer, MD, PhD

  • George D. Yancopoulos

    George D. Yancopoulos, MD, PhD

  • Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, is Regeneron’s President and Chief Scientific Officer. In 1989, he joined Len Schleifer, MD, PhD, to launch Regeneron. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Michael Aberman

    Michael Aberman, MD

  • Ned Braunstein

    Ned Braunstein, MD

  • Thomas Daly

    Thomas Daly, PhD

  • Senior Vice President, Strategy and Investor Relations

    Michael Aberman, MD, joined Regeneron in 2010, and serves as Senior Vice President, Strategy and Investor Relations. Prior to joining Regeneron, Dr. Aberman was a Wall Street research analyst covering the biotechnology industry in positions at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his MD from the University of Toronto, completed residency training in Internal Medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center and received his MBA from The Wharton School of Business.

  • Senior Vice President, Regulatory Affairs & Pharmacovigilance

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.

  • Senior Vice President, Preclinical Development & Protein Chemistry

    Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in biochemistry from Rice University and his BS in biochemistry from Hofstra University.

  • James P. Fandl

    James P. Fandl, PhD

  • Robert E. Landry

    Robert E. Landry

  • Joseph J. LaRosa

    Joseph J. LaRosa

  • Senior Vice President, Protein Expression Sciences

    James P. Fandl, PhD, joined Regeneron in 1989 as Scientist in the Protein Expression Group. During his tenure at Regeneron, Dr. Fandl has held numerous positions; he was appointed Vice President of Protein Expression Sciences in 2001 and Senior Vice President of Protein Expression Sciences in 2015. His research group developed the VelociMab® suite of proprietary technologies, including EESYR®, FASTR™, NICE® and BST, which enabled Dr. Fandl to demonstrate his knack for acronyms. He received his AB in Biology from Franklin & Marshall College and his PhD in Microbiology from the University of California, Davis.

  • Senior Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined the company in 2013 as Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Senior Vice President, General Counsel and Secretary

    Joseph J. LaRosa has been Senior Vice President, General Counsel and Secretary since September 2011. Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.

  • Beth F. Levine

    Beth F. Levine

  • Jay S. Markowitz, MD

    Jay S. Markowitz, MD

  • Andrew (Drew) Murphy

    Andrew (Drew) Murphy, PhD

  • Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Beth spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Beth was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Beth received a BS from Cornell University and a JD from Fordham Law School.

  • Senior Vice President, Portfolio Management

    Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.

  • Senior Vice President, Research, Regeneron Laboratories

    Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Senior Vice President of Regeneron Laboratories. Dr. Murphy is a co-inventor of several of Regeneron's key technologies — VelociGene® and VelocImmune® — and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • Sally A. Paull

    Sally A. Paull

  • Peter Powchik

    Peter Powchik, MD

  • Nicholas Papadopoulos

    Nicholas Papadopoulos, PhD

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at Dentsply International. She received her BA from the United States Air Force Academy and an MAIR from the University of Delaware.

  • Senior Vice President, Clinical Development

    Peter Powchik, MD, has been Senior Vice President, Clinical Development since October 2006. Prior to joining the company, Dr. Powchik served as Senior Vice President and Chief Medical Officer at Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, U.S. Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his MD from New York University School of Medicine.

  • Senior Vice President, Research & Development Operations

    Nicholas Papadopoulos, PhD, joined Regeneron in 1996 as a Scientist in the Protein Sciences Department. In 2007, Dr. Papadopoulos was named Senior Director of Therapeutic Proteins, with responsibilities dedicated to overseeing the generation of fully human VelocImmune® antibodies. He was named Vice President in 2009 and Senior Vice President in January 2015. He received his BS in Chemistry from the State University of New York and his PhD in Chemistry from The Pennsylvania State University. Dr. Papadopoulos completed his postdoctoral training in the department of Microbiology and Immunology at the Albert Einstein College of Medicine.

  • Neil Stahl

    Neil Stahl, PhD

  • Robert J. Terifay

    Robert J. Terifay

  • Daniel Van Plew

    Daniel Van Plew

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, is Executive Vice President, Research and Development. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research in 1991, working on cytokine receptor signaling. He spearheaded the invention and development of Regeneron's Trap Technology, which provided the basis of Regeneron's first three approved drugs. He also built the pre-clinical development team for the company and has overseen IND-enabling activities of over 19 therapeutic candidates. Dr. Stahl received his PhD in Biochemistry from Brandeis University, and then conducted post-doctoral research at the University of California, San Francisco before joining the company.

  • Executive Vice President, Commercial

    Robert J. Terifay is Executive Vice President, Commercial. Prior to joining Regeneron, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals, Inc.; Senior Vice President, Business Operations at Synta Pharmaceuticals, Corp.; Senior Vice President, Oncology Commercial at Millennium Pharmaceuticals, Inc.; Vice President Marketing at COR Therapeutics, Inc.; Executive Vice President of Strategic Services at Saatchi & Saatchi and held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received a Master of Management degree in Marketing and Health Service Management from the J.L. Kellogg Graduate School of Management, Northwestern University.

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. He joined the company in July 2007, previously serving as Senior Vice President, Vice President and General Manager, Industrial Operations and Product Supply. Prior to his tenure at Regeneron, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V.; Senior Director, Vacaville Operations at Chiron Biopharmaceuticals, part of Chiron Corporation; and various managerial positions in the health and life sciences practice of Accenture, Ltd. Mr. Van Plew received an MSc in Chemistry from The Pennsylvania State University and an MBA from Michigan State University.

  • David Weinreich

    David Weinreich, MD, MBA

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016.
    Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.

  • Leonard S. Schleifer

    Leonard S. Schleifer, MD, PhD

  • Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • George D. Yancopoulos

    George D. Yancopoulos, MD, PhD

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, is Regeneron’s President and Chief Scientific Officer. In 1989, he joined Len Schleifer, MD, PhD, to launch Regeneron. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Michael Aberman

    Michael Aberman, MD

  • Senior Vice President, Strategy and Investor Relations

    Michael Aberman, MD, joined Regeneron in 2010, and serves as Senior Vice President, Strategy and Investor Relations. Prior to joining Regeneron, Dr. Aberman was a Wall Street research analyst covering the biotechnology industry in positions at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his MD from the University of Toronto, completed residency training in Internal Medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center and received his MBA from The Wharton School of Business.

  • Ned Braunstein

    Ned Braunstein, MD

  • Senior Vice President, Regulatory Affairs & Pharmacovigilance

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.

  • Thomas Daly

    Thomas Daly, PhD

  • Senior Vice President, Preclinical Development & Protein Chemistry

    Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in biochemistry from Rice University and his BS in biochemistry from Hofstra University.

  • James P. Fandl

    James P. Fandl, PhD

  • Senior Vice President, Protein Expression Sciences

    James P. Fandl, PhD, joined Regeneron in 1989 as Scientist in the Protein Expression Group. During his tenure at Regeneron, Dr. Fandl has held numerous positions; he was appointed Vice President of Protein Expression Sciences in 2001 and Senior Vice President of Protein Expression Sciences in 2015. His research group developed the VelociMab® suite of proprietary technologies, including EESYR®, FASTR™, NICE® and BST, which enabled Dr. Fandl to demonstrate his knack for acronyms. He received his AB in Biology from Franklin & Marshall College and his PhD in Microbiology from the University of California, Davis.

  • Robert E. Landry

    Robert E. Landry

  • Senior Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined the company in 2013 as Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Joseph J. LaRosa

    Joseph J. LaRosa

  • Senior Vice President, General Counsel and Secretary

    Joseph J. LaRosa has been Senior Vice President, General Counsel and Secretary since September 2011. Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.

  • Beth F. Levine

    Beth F. Levine

  • Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Beth spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Beth was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Beth received a BS from Cornell University and a JD from Fordham Law School.

  • Jay S. Markowitz, MD

    Jay S. Markowitz, MD

  • Senior Vice President, Portfolio Management

    Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.

  • Andrew (Drew) Murphy

    Andrew (Drew) Murphy, PhD

  • Senior Vice President, Research, Regeneron Laboratories

    Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Senior Vice President of Regeneron Laboratories. Dr. Murphy is a co-inventor of several of Regeneron's key technologies – VelociGene® and VelocImmune® – and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • Nicholas Papadopoulos

    Nicholas Papadopoulos, PhD

  • Senior Vice President, Research & Development Operations

    Nicholas Papadopoulos, PhD, joined Regeneron in 1996 as a Scientist in the Protein Sciences Department. In 2007, Dr. Papadopoulos was named Senior Director of Therapeutic Proteins, with responsibilities dedicated to overseeing the generation of fully human VelocImmune® antibodies. He was named Vice President in 2009 and Senior Vice President in January 2015. He received his BS in Chemistry from the State University of New York and his PhD in Chemistry from The Pennsylvania State University. Dr. Papadopoulos completed his postdoctoral training in the department of Microbiology and Immunology at the Albert Einstein College of Medicine.

  • Sally A. Paull

    Sally A. Paull

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at Dentsply International. She received her BA from the United States Air Force Academy and an MAIR from the University of Delaware.

  • Peter Powchik

    Peter Powchik, MD

  • Senior Vice President, Clinical Development

    Peter Powchik, MD, has been Senior Vice President, Clinical Development since October 2006. Prior to joining the company, Dr. Powchik served as Senior Vice President and Chief Medical Officer at Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, U.S. Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his MD from New York University School of Medicine.

  • Neil Stahl

    Neil Stahl, PhD

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, is Executive Vice President, Research and Development. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research in 1991, working on cytokine receptor signaling. He spearheaded the invention and development of Regeneron's Trap Technology, which provided the basis of Regeneron's first three approved drugs. He also built the pre-clinical development team for the company and has overseen IND-enabling activities of over 19 therapeutic candidates. Dr. Stahl received his PhD in Biochemistry from Brandeis University, and then conducted post-doctoral research at the University of California, San Francisco before joining the company.

  • Robert J. Terifay

    Robert J. Terifay

  • Executive Vice President, Commercial

    Robert J. Terifay is Executive Vice President, Commercial. Prior to joining Regeneron, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals, Inc.; Senior Vice President, Business Operations at Synta Pharmaceuticals, Corp.; Senior Vice President, Oncology Commercial at Millennium Pharmaceuticals, Inc.; Vice President Marketing at COR Therapeutics, Inc.; Executive Vice President of Strategic Services at Saatchi & Saatchi and held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received a Master of Management degree in Marketing and Health Service Management from the J.L. Kellogg Graduate School of Management, Northwestern University.

  • Daniel Van Plew

    Daniel Van Plew

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. He joined the company in July 2007, previously serving as Senior Vice President, Vice President and General Manager, Industrial Operations and Product Supply. Prior to his tenure at Regeneron, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V.; Senior Director, Vacaville Operations at Chiron Biopharmaceuticals, part of Chiron Corporation; and various managerial positions in the health and life sciences practice of Accenture, Ltd. Mr. Van Plew received an MSc in Chemistry from The Pennsylvania State University and an MBA from Michigan State University.

  • David Weinreich

    David Weinreich, MD, MBA

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.

  • P. Roy Vagelos, MD

    P. Roy Vagelos, MD

  • Charles A. Baker

    Charles A. Baker

  • Bonnie L. Bassler, PhD

    Bonnie L. Bassler, PhD

  • Chairman of the Board; Retired Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

    P. Roy Vagelos, MD, has been Chairman of the Board of the company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985 and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010.

  • Retired Chairman of the Board; President and Chief Executive Officer of The Liposome Company, Inc.

    Charles A. Baker has been a Director of the company since February 1989. In September 2000, Mr. Baker retired as Chairman, President and Chief Executive Officer of The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb); President, Squibb International; and various senior executive positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker is currently a member of the Board of Directors of Progenics Pharmaceuticals, Inc.

  • Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University

    Bonnie L. Bassler, PhD, joined the board in 2016. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University.

  • Michael S. Brown, MD

    Michael S. Brown, MD

  • Tony Coles, MD

    Tony Coles, MD

  • Joseph L. Goldstein, MD

    Joseph L. Goldstein, MD

  • Regental Professor of Molecular Genetics and Internal Medicine, Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southwestern Medical Center at Dallas

    Michael S. Brown, MD, has been a Director of the company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine and the Director of the Erik Jonsson Center for Molecular Genetics and Human Disease at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer Inc. until April 2012.

  • Chairman and Chief Executive Officer, Yumanity Therapeutics, LLC

    Dr. Coles, age 56, has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors. He has also served as Chairman of the board of directors of CRISPR Therapeutics AG since October 2015 and serves on its Compensation Committee and Nominating and Corporate Governance Committee.

  • Regental Professor and Chairman, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas

    Joseph L. Goldstein, MD, has been a Director of the company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.

  • Christine A. Poon

    Christine A. Poon

  • Arthur F. Ryan

    Arthur F. Ryan

  • Leonard S. Schleifer, MD, PhD

    Leonard S. Schleifer, MD, PhD

  • Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business, The Ohio State University

    Christine A. Poon has been a director of the company since 2010. Ms. Poon is a Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004, and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.

  • Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc.

    Arthur F. Ryan has been a Director of the company since January 2003. In 2008, Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank, where he also ran Chase's worldwide retail bank. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc.

  • President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception, and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia; he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • George L. Sing

    George L. Sing

  • Marc Tessier-Lavigne, PhD

    Marc Tessier-Lavigne, PhD

  • George D. Yancopoulos, MD, PhD

    George D. Yancopoulos, MD, PhD

  • Managing Director, Lancet Capital

    George L. Sing has been a Director of the company since January 1988, during which time he also held the position of Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Mr. Sing has also served as Chief Executive Officer of Stemnion, Inc., a biomedical company in the regenerative medicine field.

  • President, The Rockefeller University

    Marc Tessier-Lavigne, PhD, has been a Director of the company since November 2011. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. From March 2011 to August 2016, he served as the President of The Rockefeller University. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford and at the University of California, San Francisco. Dr. Tessier-Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, joined the company in 1989 and is President and Chief Scientific Officer. Dr. Yancopoulos has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Huda Y. Zoghbi, MD

    Huda Y. Zoghbi, MD

  • Professor, Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience, Baylor College

    Director, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital

    Huda Y. Zoghbi, MD, joined the board in 2016. Dr. Zoghbi is currently a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital and an investigator of the Howard Hughes Medical Institute. She has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science, and has been awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science. Dr. Zoghbi earned her BSc from the American University of Beirut, received her MD from Meharry Medical College in Nashville, TN, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.

  • P. Roy Vagelos, MD

    P. Roy Vagelos, MD

  • Chairman of the Board; Retired Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

    P. Roy Vagelos, MD, has been Chairman of the Board of the company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985 and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010.

  • Charles A. Baker

    Charles A. Baker

  • Retired Chairman of the Board; President and Chief Executive Officer of The Liposome Company, Inc.

    Charles A. Baker has been a Director of the company since February 1989. In September 2000, Mr. Baker retired as Chairman, President and Chief Executive Officer of The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb); President, Squibb International; and various senior executive positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker is currently a member of the Board of Directors of Progenics Pharmaceuticals, Inc.

  • Bonnie L. Bassler, PhD

    Bonnie L. Bassler, PhD

  • Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University

    Bonnie L. Bassler, PhD, joined the board in 2016. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University.

  • Michael S. Brown, MD

    Michael S. Brown, MD

  • Regental Professor of Molecular Genetics and Internal Medicine, Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southwestern Medical Center at Dallas

    Michael S. Brown, MD, has been a Director of the company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine and the Director of the Erik Jonsson Center for Molecular Genetics and Human Disease at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer Inc. until April 2012.

  • Tony Coles, MD

    Tony Coles, MD

  • Chairman and Chief Executive Officer, Yumanity Therapeutics, LLC

    Dr. Coles, age 56, has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors. He has also served as Chairman of the board of directors of CRISPR Therapeutics AG since October 2015 and serves on its Compensation Committee and Nominating and Corporate Governance Committee.

  • Joseph L. Goldstein, MD

    Joseph L. Goldstein, MD

  • Regental Professor and Chairman, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas

    Joseph L. Goldstein, MD, has been a Director of the company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.

  • Christine A. Poon

    Christine A. Poon

  • Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business, The Ohio State University

    Christine A. Poon has been a director of the company since 2010. Ms. Poon is a Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004, and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.

  • Arthur F. Ryan

    Arthur F. Ryan

  • Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc.

    Arthur F. Ryan has been a Director of the company since January 2003. In 2008, Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank, where he also ran Chase's worldwide retail bank. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc.

  • Leonard S. Schleifer, MD, PhD

    Leonard S. Schleifer, MD, PhD

  • President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception, and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia; he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • George L. Sing

    George L. Sing

  • Managing Director, Lancet Capital

    George L. Sing has been a Director of the company since January 1988, during which time he also held the position of Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Mr. Sing has also served as Chief Executive Officer of Stemnion, Inc., a biomedical company in the regenerative medicine field.

  • Marc Tessier-Lavigne, PhD

    Marc Tessier-Lavigne, PhD

  • President, The Rockefeller University

    Marc Tessier-Lavigne, PhD, has been a Director of the company since November 2011. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. From March 2011 to August 2016, he served as the President of The Rockefeller University. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford and at the University of California, San Francisco. Dr. Tessier-Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.

  • George D. Yancopoulos, MD, PhD

    George D. Yancopoulos, MD, PhD

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, joined the company in 1989 and is President and Chief Scientific Officer. Dr. Yancopoulos has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Huda Y. Zoghbi, MD

    Huda Y. Zoghbi, MD

  • Professor, Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience, Baylor College

    Director, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital

    Huda Y. Zoghbi, MD, joined the board in 2016. Dr. Zoghbi is currently a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital and an investigator of the Howard Hughes Medical Institute. She has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science, and has been awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science. Dr. Zoghbi earned her BSc from the American University of Beirut, received her MD from Meharry Medical College in Nashville, TN, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.